Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc (NY: ZYME )

6.430 UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc

< Previous 1 2 3 4 5 6 7 8 Next >
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In... 
Via Benzinga
Zymeworks To Cut Its Workforce By Almost 25%, Outlines 2022 & 2023 Priorities
Zymeworks Inc (NYSE: ZYME) said that in conjunction with the renewed focus on key priorities and cost-efficiency, ten members (or 50%) of the former senior management team... 
Via Benzinga
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
From Zymeworks Inc.
Via Business Wire
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
From Zymeworks Inc.
Via Business Wire
Post-Fed Thursday
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this... 
Via Benzinga
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
From Zymeworks Inc.
Via Business Wire
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
From Zymeworks Inc.
Via Business Wire
Raising Rates
The Bank of England raised its interest rate to 0.25%, setting a pattern for other countries. 
Via Talk Markets
To sell or not to sell?
Pfizer says its covid pill is 90% effective. PFE got higher target prices from Berenburg and Mizuho 
Via Talk Markets
Inflation Surge
Today the market failed to brush off inflation fears as it had done later on Thursday as inflation is at a 4 decade high. 
Via Talk Markets
Omicron Surge
The seemingly good level of joblessness at a mere 184,000 turns out to be less wonderful than it appears, at the lowest since 1969. 
Via Talk Markets
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
From Zymeworks Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021
Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE: 
Via Benzinga
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
From Zymeworks Inc.
Via Business Wire
56 Biggest Movers From Yesterday
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares jumped 84% to close at $4.95 on Thursday after the company signed an exclusive summary distribution agreement... 
Via Benzinga
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Happy December
Inflation levels this year will almost certainly lower growth in 2022 because of inflation this year in everything from house prices....to stock prices. 
Via Talk Markets
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
From Zymeworks Inc.
Via Business Wire
Tuesday Markets Review
The oil price did not fall as expected over the White House release of 50 mn bbls of oil. 
Via Talk Markets
Tuesday Markets Coverage
GE was up on hopes for cheaper oil. But most stocks were down on oil price hike fears. 
Via Talk Markets
Friday Markets Coverage
Today markets are suffering alongside Austria which locked down against Covid-19 again. 
Via Talk Markets
Exposures COVID-19
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
From Zymeworks Inc.
Via Business Wire
Tuesday Market Overview
While gold gained modestly again today, cryptocurrencies fell hard. 
Via Talk Markets
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer
From Zymeworks Inc.
Via Business Wire
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
From Zymeworks Inc.
Via Business Wire
Zymeworks to Present at Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Thursday Market Overview
If you are an IBM shareholder you now own something new Kyndryl. 
Via Talk Markets
Zymeworks Reports 2021 Third Quarter Financial Results
From Zymeworks Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.